(Oslo, 15 June 2016) Navamedic ASA ("Navamedic", OSE: NAVA) today announced that the Swedish Patent and Registration Office has granted a new patent pertaining to Sippcoat®, broadening the innovative encapsulated silicone-oil technology for biofilm inhibition to any patient drainage device.
"We are pleased with the positive news about the patent granted for Sippcoat, a part of the Sippi family that allows for sterile release of silicone oil to prevent biofilm build-up. This is an important milestone for the Sippcoat® technology as it expands the use from urology systems to all fluid drainage devices. With the increased scope and opportunities for multiple disciplines of products, we are broadening our approach in offering Sippcoat® to the market as well as adding to the long term commercial opportunity for the Sippi® product family," says Tom Rönnlund, CEO of Navamedic.
The announcement from the Swedish Patent and Registration Office relates to a non-toxic, environmentally sustainable method for sterile release of Sippcoat® biofilm inhibitor within any patient bodily drainage device. Biofilm formation has a causal link to nearly all hospital acquired infections and the product, which prevents bacterial colonization and inhibits biofilm build-up, thus represents major value to hospitals and patients across the world.
"The newly granted patent, one of now five filed or granted patent families in the Sippi® product range, is an exciting development for Navamedic and the future of the Sippi® product family. We have initiated additional studies to add to the growing body of clinical evidence showing the benefits of the Sippcoat® technology, and look forward to expanding the simple and sustainable method for sterilising body fluid drainage systems and preventing biofilm build-up, not only within urology, but across a number of specialities," says Magnus Emmoth, Head of Medtech at Navamedic.
For further information, please contact:
Tom Rönnlund, CEO Navamedic
Telephone: +46 727 320 321
Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to patients, hospitals and pharmacies in the Nordic and Benelux markets. The Group's Medtech business has developed, and is currently introducing, the next generation of digital urine meter, Sippi®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).